Market Need Spirox targets a large U.S. patient population with nasal obstruction and nasal valve collapse, creating a sizable opportunity to partner with ENT clinics, rhinologists, and hospital systems to drive LATERA adoption.

Expansion Potential LATERA is currently US only; pursuing international regulatory approvals or distribution partnerships could unlock growth in new markets and broaden the sales opportunity.

Strategic Financing Historical backing from KKR and a past acquisition by Entellus signals strong investor interest and potential for strategic partnerships, co marketing, or distribution agreements to accelerate sales.

Scale and Ops A lean organization with limited headcount suggests opportunity to collaborate on manufacturing scale, supply chain, and regulatory support to meet growing demand.

Digital Selling A modern tech stack including Odoo, Marketo, and PWA provides a solid foundation for targeted digital marketing, lead generation, and partner enablement with ENT networks.